Spending the cost of Bortezomib ACTe launch for the first injection of patients in need.

October 20, 2020

Author: Acteropharma

Considering the current situation in the country and taking into account the needs of patients, Actero Company decided to spend all the costs related to the unveiling of the drug Bortezomib ACTe on the first free injection of patients’ candidates receiving Bortezomib. Therefore, by delivering the drug sample to physicians specializing in this field, treatment coverage began in a number of eligible patients.

Last News

EHA 2023 Actero Sponsorship

EHA 2023
June 26, 2023



Actero Support in Congress 1400

July 24, 2022


Actero company’s social respomsibility of patient support in Hematology-Oncology Congress and Radiation Therapy Congress

Best of ASCO 2021

November 16, 2021


The aforesaid seminar has been held for the first time in Iran with the hospitality of Isfahan city, with the cooperation of Radiation-Oncologists from all over of the country and Actero Pharma.